3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
3
Recruiting
2
Active not recruiting
2
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Other neoplasm
1
Conditions
Endometrial Neoplasms
2
Uterine Prolapse
1
Uterine Cervical Neoplasms
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Menstruation Disturbances
1
Leiomyoma
1
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
1
Endometriosis
1
Carcinoma, Endometrioid
1
Adenomyosis
1
Interventions
pembrolizumab
15
Paclitaxel
15
Carboplatin
13
Specimen Handling
6
Biopsy
6
durvalumab
5
Magnetic Resonance Spectroscopy
5
dostarlimab
4
Taxes
4
Surveys and Questionnaires
4
Observation
4
Letrozole
4
Everolimus
4
Cisplatin
4
olaparib
3
lenvatinib
3
ceralasertib
3
Doxorubicin
3
sacituzumab govitecan
2
pertuzumab
2
copanlisib
2
cabozantinib
2
atezolizumab
2
abemaciclib
2
Trastuzumab
2
Robotic Surgical Procedures
2
Pemetrexed
2
Nivolumab
2
Metformin
2
Megestrol Acetate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Endometrial Neoplasms
×
Hysterectomy
×
Clear all
NCT07120945
2026-06-02
Embrace Gyn
Medtronic - MITG
Phase NA
Active not recruiting
70 enrolled
NCT06800677
2025-01-30
BioMEC
University of Manchester
Active not recruiting
200 enrolled